DK3298030T3 - Anti-cancerfusionspolypeptid - Google Patents

Anti-cancerfusionspolypeptid Download PDF

Info

Publication number
DK3298030T3
DK3298030T3 DK16729794.4T DK16729794T DK3298030T3 DK 3298030 T3 DK3298030 T3 DK 3298030T3 DK 16729794 T DK16729794 T DK 16729794T DK 3298030 T3 DK3298030 T3 DK 3298030T3
Authority
DK
Denmark
Prior art keywords
cancerfusionspolypeptid
Prior art date
Application number
DK16729794.4T
Other languages
English (en)
Inventor
Marlon Hinner
Aiba Rachida Siham Bel
Christine Rothe
Shane Olwill
Corinna Schlosser
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Application granted granted Critical
Publication of DK3298030T3 publication Critical patent/DK3298030T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16729794.4T 2015-05-18 2016-05-18 Anti-cancerfusionspolypeptid DK3298030T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167927 2015-05-18
EP16150508 2016-01-08
PCT/EP2016/061071 WO2016184882A1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide

Publications (1)

Publication Number Publication Date
DK3298030T3 true DK3298030T3 (en) 2023-02-06

Family

ID=56134305

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16729794.4T DK3298030T3 (en) 2015-05-18 2016-05-18 Anti-cancerfusionspolypeptid

Country Status (22)

Country Link
US (2) US10913778B2 (da)
EP (2) EP3298030B1 (da)
JP (1) JP6947642B2 (da)
KR (1) KR20180002855A (da)
CN (1) CN108112253B (da)
AU (1) AU2016262845B2 (da)
BR (1) BR112017020445A2 (da)
CA (1) CA2980838A1 (da)
DK (1) DK3298030T3 (da)
ES (1) ES2938525T3 (da)
FI (1) FI3298030T3 (da)
HR (1) HRP20230145T1 (da)
HU (1) HUE061108T2 (da)
LT (1) LT3298030T (da)
MX (1) MX2017014716A (da)
PL (1) PL3298030T3 (da)
RS (1) RS64002B1 (da)
RU (2) RU2754466C2 (da)
SG (1) SG11201707426SA (da)
SI (1) SI3298030T1 (da)
WO (1) WO2016184882A1 (da)
ZA (1) ZA201706061B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927154B2 (en) * 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
WO2016177762A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US10501510B2 (en) 2015-07-15 2019-12-10 Pieris Pharmaceuticals Gmbh Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA47200A (fr) * 2017-01-03 2019-11-13 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
WO2018127710A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
EP3571219A1 (en) * 2017-01-18 2019-11-27 Pieris Pharmaceuticals GmbH Lipocalin muteins with binding affinity for lag-3
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
JP7312168B2 (ja) * 2017-11-13 2023-07-20 クレッシェンド、バイオロジックス、リミテッド Cd137に結合するシングルドメイン抗体
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
KR20200136949A (ko) 2018-03-26 2020-12-08 4에스체 악티엔게젤샤프트 암 치료를 위한 hdac 억제제 및 cd137 작용제를 포함하는 배합물
KR20210040103A (ko) * 2018-07-31 2021-04-12 피어이스 파마슈티컬즈 게엠베하 Cd137 및 pd-l1에 특이적인 신규한 융합 단백질
SG11202106353VA (en) 2019-02-26 2021-07-29 Pieris Pharmaceuticals Gmbh Novel fusion proteins specific for cd137 and gpc3
EP3952996A1 (en) * 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
AU2020260931B2 (en) * 2019-04-23 2023-08-24 Lg Chem, Ltd. Fusion polypeptide comprising Fc region of immunoglobulin and GDF15
BR112021026376A2 (pt) * 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
WO2024064713A1 (en) * 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE69534318T2 (de) 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (fr) 1996-10-14 1998-04-23 Firm Forsat Ltd. Procede de preparation de dispersions a base de composants chromogenes
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
SI1087778T1 (sl) 1998-06-08 2006-02-28 Hoffmann La Roche Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
CA2659413C (en) 2006-08-01 2016-06-14 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
ES2354653T3 (es) 2006-08-01 2011-03-16 Pieris Ag Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas.
PT2178921E (pt) 2007-07-17 2016-03-23 Squibb & Sons Llc Anticorpos monoclonais contra glipicano-3
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
AU2009264214B2 (en) 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
US9549968B2 (en) 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
RU2551963C2 (ru) * 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
AU2011331232B2 (en) 2010-11-15 2015-05-07 Pieris Ag Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
US9522940B2 (en) * 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
AU2013359429A1 (en) * 2012-12-10 2015-07-09 Fred Hutchinson Cancer Research Center Methods for screening
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN107460201A (zh) * 2013-05-08 2017-12-12 科济生物医药(上海)有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
NZ724710A (en) * 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
EP3250586B1 (en) 2015-01-28 2021-10-27 Pieris Pharmaceuticals GmbH Novel proteins specific for angiogenesis
JP6843754B2 (ja) 2015-02-18 2021-03-17 ピエリス ファーマシューティカルズ ゲーエムベーハー ピオベルジン及びピオケリンに特異的な新規なタンパク質
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3298029A1 (en) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Also Published As

Publication number Publication date
KR20180002855A (ko) 2018-01-08
RU2021119777A (ru) 2021-08-16
BR112017020445A2 (pt) 2018-07-03
EP3298030B1 (en) 2023-01-18
CN108112253B (zh) 2022-09-23
SG11201707426SA (en) 2017-10-30
ES2938525T3 (es) 2023-04-12
PL3298030T3 (pl) 2023-05-08
HRP20230145T1 (hr) 2023-04-28
RU2017135539A (ru) 2019-06-18
US20210403516A1 (en) 2021-12-30
RU2754466C2 (ru) 2021-09-02
FI3298030T3 (fi) 2023-02-22
ZA201706061B (en) 2022-05-25
AU2016262845B2 (en) 2020-07-23
LT3298030T (lt) 2023-02-27
US11919931B2 (en) 2024-03-05
JP6947642B2 (ja) 2021-10-13
US10913778B2 (en) 2021-02-09
RS64002B1 (sr) 2023-03-31
EP3298030A1 (en) 2018-03-28
CA2980838A1 (en) 2016-11-24
SI3298030T1 (sl) 2023-05-31
CN108112253A (zh) 2018-06-01
EP4219535A1 (en) 2023-08-02
WO2016184882A1 (en) 2016-11-24
AU2016262845A1 (en) 2018-01-04
RU2017135539A3 (da) 2019-11-29
US20180148485A1 (en) 2018-05-31
MX2017014716A (es) 2018-06-28
HUE061108T2 (hu) 2023-05-28
JP2018519803A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
DK3389557T3 (en) Transseptalt leveringssystem
DK3320033T3 (en) Polyethylenterephthalat-depolymerisering
DK3256579T3 (en) Cysteinprotease
DK3256580T3 (en) Cysteinprotease
DK3298030T3 (en) Anti-cancerfusionspolypeptid
DK3250592T3 (en) Anti-transthyretin-antistoffer
DK3373882T3 (en) Patientisolator
DK3284069T3 (en) Pos-terminal
GB201500806D0 (en) Aerosol-gnerating aticle
DK3390996T3 (en) Trykbart tids-temperaturindikatorsystem
DK3380145T3 (en) Injektionsapparat
DK3336185T3 (en) Antistof
DK3272750T3 (en) Morphinan-derivat
GB201501723D0 (en) Winics
DK3324768T3 (en) Tørdragt
AU361999S (en) Ballustrade
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3282866T3 (en) Proteinfibre
DK3250312T3 (en) Urea-metalnitrat-scr-system
DK3294653T3 (en) Justerbar inline-port
DK3242882T3 (en) Cgrp-antagonistpeptider
AU5516P (en) LEP08 Lepidosperma squamatum
AU5511P (en) PTK647 Epichloe coenophiala
AU366552S (en) Nutblock
AU367131S (en) USB-charger